Gyre Therapeutics (NASDAQ:GYRE) Hits New 1-Year Low – What’s Next?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) reached a new 52-week low during trading on Friday . The company traded as low as $6.57 and last traded at $6.6150, with a volume of 61637 shares traded. The stock had previously closed at $7.00.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GYRE. Weiss Ratings lowered Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Wall Street Zen lowered Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Zacks Research lowered Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Performance

The stock has a 50-day moving average of $7.43 and a 200-day moving average of $7.65. The firm has a market cap of $635.53 million, a price-to-earnings ratio of -72.77 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE) last announced its earnings results on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. The firm had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million. Sell-side analysts predict that Gyre Therapeutics, Inc. will post -0.3 EPS for the current fiscal year.

Insider Transactions at Gyre Therapeutics

In related news, CEO Ying Luo sold 10,136 shares of Gyre Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total value of $81,493.44. Following the sale, the chief executive officer owned 2,565,226 shares of the company’s stock, valued at approximately $20,624,417.04. This trade represents a 0.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its position in Gyre Therapeutics by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock valued at $301,000 after buying an additional 1,941 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Gyre Therapeutics by 131.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after purchasing an additional 14,365 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Gyre Therapeutics by 28.6% during the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after purchasing an additional 89,390 shares during the last quarter. State Street Corp increased its position in shares of Gyre Therapeutics by 10.7% during the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after purchasing an additional 19,472 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.